Who is sponsoring NCT05905315?

NCT05905315 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT05905315?

Interventions in NCT05905315: Paclitaxel and Carboplatin, Chemoradiation.

What condition does NCT05905315 study?

NCT05905315 studies Locally Advanced Vulvar Carcinoma, Squamous Cell Carcinoma of the Vulva.

Is NCT05905315 still recruiting?

NCT05905315 is currently recruiting now. Last updated 15 April 2024.

Last reviewed 2024-04-15 · How we verify

NCT05905315: VULCANIZE-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC

Recruiting now Phase 2 Last updated 15 April 2024

What this trial tests

Phase 2 trial testing Paclitaxel and Carboplatin in Locally Advanced Vulvar Carcinoma in 98 participants. Currently enrolling.

Timeline

1 January 2024

Primary endpoint
1 September 2029

1 September 2029

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	1 January 2024
Primary completion	1 September 2029
Estimated completion	1 September 2029
Sites	2 locations across Netherlands

Drugs / interventions tested

Paclitaxel and Carboplatin — full drug profile →
Chemoradiation — full drug profile →

Conditions studied

Locally Advanced Vulvar Carcinoma — all drugs for Locally Advanced Vulvar Carcinoma →
Squamous Cell Carcinoma of the Vulva — all drugs for Squamous Cell Carcinoma of the Vulva →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, female only, with Locally Advanced Vulvar Carcinoma or Squamous Cell Carcinoma of the Vulva. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT; consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98 patients with LAVC, registered from eight national medical centres.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2).
Amant F, van Velzen AF, Reyners A, Zijlmans H, et al · · 2024 · cited 2× · PMID 38719277 · DOI 10.1136/ijgc-2024-005493

Verify or expand the search:

Other trials of Paclitaxel and Carboplatin

Trials testing the same drug.

NCT04161664 — Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy · Phase 2 · recruiting
NCT04192253 — Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VU · Phase 2 · recruiting

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05905315 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 15 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05905315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing